Singh, R. P., Lehmann, R., Martel, J., Jong, K., Pollack, A., Tsorbatzoglou, A., … Jaffe, G. J. (2018). Re: Singh et al.: Nepafenac 0.3% after cataract surgery in patients with diabetic retinopathy: result of 2 randomized phase 3 studies (Ophthalmology. 2017; 124: 776-785) REPLY. OPHTHALMOLOGY, 125(1), E9–E10.

Singh, Rishi P., Robert Lehmann, Joseph Martel, Kevin Jong, Ayala Pollack, Alexis Tsorbatzoglou, Giovanni Staurenghi, et al. “Re: Singh et al.: Nepafenac 0.3% after cataract surgery in patients with diabetic retinopathy: result of 2 randomized phase 3 studies (Ophthalmology. 2017; 124: 776-785) REPLY.” OPHTHALMOLOGY 125, no. 1 (January 1, 2018): E9–10.

Singh RP, Lehmann R, Martel J, Jong K, Pollack A, Tsorbatzoglou A, et al. Re: Singh et al.: Nepafenac 0.3% after cataract surgery in patients with diabetic retinopathy: result of 2 randomized phase 3 studies (Ophthalmology. 2017; 124: 776-785) REPLY. OPHTHALMOLOGY. 2018 Jan 1;125(1):E9–10.

Singh, Rishi P., et al. “Re: Singh et al.: Nepafenac 0.3% after cataract surgery in patients with diabetic retinopathy: result of 2 randomized phase 3 studies (Ophthalmology. 2017; 124: 776-785) REPLY.” OPHTHALMOLOGY, vol. 125, no. 1, ELSEVIER SCIENCE INC, Jan. 2018, pp. E9–10.

Singh RP, Lehmann R, Martel J, Jong K, Pollack A, Tsorbatzoglou A, Staurenghi G, Cervantes-Coste Cervantes G, Alpern L, Modi S, Svoboda L, Adewale A, Jaffe GJ. Re: Singh et al.: Nepafenac 0.3% after cataract surgery in patients with diabetic retinopathy: result of 2 randomized phase 3 studies (Ophthalmology. 2017; 124: 776-785) REPLY. OPHTHALMOLOGY. ELSEVIER SCIENCE INC; 2018 Jan 1;125(1):E9–E10.